Rheumatoid Arthritis Beyond cs-DMARD The management of rheumatoid arthritis (RA) mainly focuses on increasing bone mineral density and reducing fragility fractures in affected patients. Patients with RA are mostly treated with a conventional synthetic disease-modifying anti-rheumatic drug (csDMARD). However, other treatment strategies, including biologic or targeted synthetic disease-modifying drugs, can also be used for better clinical outcomes.
Nevertheless, decision-making by rheumatologists is crucial to choose appropriate treatment strategies and to observe the effects of bone architecture and other bone-related parameters. Heart Failure – INTERMACS & Use of LVADs (MCDs) Despite significant advancements in pharmacological therapy and pacing, advanced heart failure (HF) still shows a poor prognosis with 25–50% mortality within one year. However, implantable left ventricular…
